All In Biotech

Drug Trial Radar · NCT02111564

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk

Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,024 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,024

Actual

Start

Jan 7, 2014

Primary completion

Mar 6, 2018

Study completion May 3, 2018

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Bayer
First posted
Apr 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.

Conditions

  • Heart Failure
  • Respiratory Insufficiency
  • Stroke Acute
  • Infectious Diseases
  • Rheumatic Diseases

Interventions

  • Rivaroxaban, 10 mgDrug

    Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.

  • Rivaroxaban, 7.5 mgDrug

    Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.

  • PlaceboDrug

    All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)Time frame: Up to Day 45
  2. Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CECTime frame: From randomization to 2 days after the last dose (Day 45)

Locations

593 sites in 37 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Sheffield, Alabama

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Fort Smith, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Fullerton, California

  • Site not named

    Los Angeles, California

  • Site not named

    Newport Beach, California

  • Site not named

    Orange, California

  • Site not named

    Sacramento, California

  • Site not named

    San Jose, California

  • Site not named

    San Marino, California

  • Site not named

    Santa Ana, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Bridgeport, Connecticut

  • Site not named

    Danbury, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Atlantis, Florida

  • Site not named

    Bay Pines, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Brandon, Florida

  • Site not named

    Celebration, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville Beach, Florida

  • Site not named

    Largo, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Saint Cloud, Florida

  • Site not named

    Sebring, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    Wellington, Florida

Showing 40 of 593 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.